RVL Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. The Company is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. It operates in one business segment which focuses on developing and commercializing pharmaceutical products. The Company is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.

Employees

125

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
15/07/26	$0.000001	0.00%	124,651
10/07/26	$0.000001	0.00%	5,000

Delayed Quote OTC Markets

More quotes

Delayed OTC Markets Other stock markets 19:53:25 15/07/2026 +03			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

05-01	Rvl Pharmaceuticals Launches Upneeq Reveal Under Eye Complex	CI
04/11/24	RVL Pharmaceuticals plc (OTCPK:RVLP.Q) cancelled the acquisition of acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc..	CI

Market Cap	334K 292K 270K 248K 468K 32.19M 479K 3.22M 1.27M 15.76M 1.26M 1.23M 54.26M	P/E 2021	-1.12x	P/E 2022	-1.95x
Enterprise Value	13.28M 11.61M 10.71M 9.87M 18.61M 1.28B 19.02M 128M 50.35M 626M 49.87M 48.78M 2.16B	EV / Sales 2021	5.55x	EV / Sales 2022	2.49x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

05-01	Rvl Pharmaceuticals Launches Upneeq Reveal Under Eye Complex	CI
04/11/24	RVL Pharmaceuticals plc (OTCPK:RVLP.Q) cancelled the acquisition of acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc..	CI
29/10/24	RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. for $11.5 million.	CI
25/10/23	RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from S&P TMI Index	CI
20/10/23	RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from NASDAQ Composite Index	CI
12/10/23	Health Care Down as Risk Aversion Hurts Biotech -- Health Care Roundup	DJ
12/10/23	Top Midday Decliners	MT
12/10/23	RVL Pharmaceuticals Subsidiaries File for Prepackaged Chapter 11 Change of Control to Lenders	MT
29/09/23	Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	MT
29/09/23	Top Premarket Gainers	MT
22/09/23	RVL Pharmaceuticals plc Announces Resignation of Joaquin Benes and Juan Vergez from the Board of Directors	CI
21/08/23	HC Wainwright Adjusts RVL Pharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	MT
16/08/23	Top Midday Decliners	MT

21/08/23	HC Wainwright Adjusts RVL Pharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	MT
01/05/23	Barclays Adjusts Price Target on RVL Pharmaceuticals to $2 From $3, Keeps Overweight Rating	MT
25/10/22	Barclays Adjusts Price Target on RVL Pharmaceuticals to $3 From $4, Reiterates Overweight Rating	MT
21/10/22	Jefferies Assumes RVL Pharmaceuticals at Hold With $2.50 Price Target	MT
05/04/22	Barclays Reinstates RVL Pharmaceuticals at Overweight With $4 Price Target	MT

RVL Pharmaceuticals plc Stock

Stocks

RVLPQ

IE00BF2HDL56

Biotechnology & Medical Research

Valuation: RVL Pharmaceuticals plc

Chart: RVL Pharmaceuticals plc

Latest news : RVL Pharmaceuticals plc

Analysts' recommendations: RVL Pharmaceuticals plc

Press Releases: RVL Pharmaceuticals plc

News in other languages: RVL Pharmaceuticals plc

Course Extremes

Managers and Directors: RVL Pharmaceuticals plc

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

20/05/24	RVL Pharmaceuticals - Upneeq Wins 2024 Shape Skin Award, 'Best for Lift', in the Professional Treatment Category	AQ
12/10/23	RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries	AQ
26/08/23	RVL Pharmaceuticals : Regulation FD Disclosure - Form 8-K	PU
23/08/23	RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference	AQ
16/08/23	RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	AQ

08/05/24	Relief Therapeutics réorganise entièrement sa direction
31/12/20	Emergent BioSolutions : MÄRKTE USA/Dow-Jones schließt mit kleinen Gewinnen auf Rekordhoch
30/12/20	Emergent BioSolutions : MÄRKTE USA/Börsen in ruhigem Geschäft leicht im Plus
30/12/20	Emergent BioSolutions : MÄRKTE USA/Börsen mit leichten Aufschlägen zum Start
30/12/20	Emergent BioSolutions : MARKT USA/Börsen mit moderaten Aufschlägen erwartet

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.5
5 years	0		4.38
10 years	0		9.9

Manager	Title	Age	Since
James Schaub COO	Chief Operating Officer	44	01/01/2016
Jarret Miller HRO	Human Resources Officer	-	01/01/2016

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/19/23 A	Altchem Ltd.	Sell	Company	14,122,659	12.6767%
10/19/23 A	Altchem Ltd.	Sell	Company	14,122,659	12.6767%
10/18/23 A	Altchem Ltd.	Sell	Company	3,421,537	3.0712%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RVL PHARMACEUTICALS PLC	0.00%	0.00%	-	-	111
LONZA GROUP AG	-1.29%	-3.11%	-0.39%	+4.92%	49.7B
REVOLUTION MEDICINES, INC.	+3.00%	-1.69%	+370.50%	+590.45%	38.09B
BEONE MEDICINES AG	-1.76%	+4.44%	+7.44%	+57.64%	35.29B
IQVIA HOLDINGS INC.	-2.05%	-0.51%	+26.68%	-6.58%	35.13B
CELLTRION, INC.	+0.06%	+1.56%	+4.41%	+27.42%	27.22B
ASCENDIS PHARMA A/S	+2.36%	-1.68%	-	-	16.14B
MEDPACE HOLDINGS, INC.	-0.66%	-0.70%	+67.46%	+116.06%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+15.90%	+19.65%	13.89B
ICON PUBLIC LIMITED COMPANY	-0.15%	+1.14%	+15.50%	-30.77%	13.02B
Average	+0.01%	-0.51%	+63.44%	+97.35%	24.38B
Weighted average by Cap.	-0.24%	-0.64%	+74.10%	+118.31%

	2021	2022
Net sales	17.5M 15.29M 14.11M 13.01M 24.52M 1.69B 25.06M 169M 66.35M 825M 65.73M 64.28M 2.84B	49.72M 43.45M 40.1M 36.96M 69.66M 4.79B 71.21M 479M 188M 2.35B 187M 183M 8.07B
Net income	-64.92M -56.73M -52.35M -48.26M -90.95M -6.25B -92.97M -626M -246M -3.06B -244M -238M -10.54B	-51.69M -45.17M -41.68M -38.42M -72.42M -4.98B -74.03M -498M -196M -2.44B -194M -190M -8.39B
Net Debt	7.2M 6.29M 5.81M 5.35M 10.09M 693M 10.31M 69.41M 27.3M 340M 27.04M 26.45M 1.17B	12.95M 11.31M 10.44M 9.62M 18.14M 1.25B 18.54M 125M 49.08M 611M 48.62M 47.55M 2.1B